Home › Companies › PROTAGONIST THERAPEUTICS INC. › 2023-2024

PROTAGONIST THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and PROTAGONIST THERAPEUTICS INC.’s Form 8-K, filed June 26, 2024 (Item 5.07 on EDGAR). Page generated October 18, 2026.

6Ballot items
209Asset managers
1,450Fund votes
June 20, 2024Meeting date

Results at a glance

Meeting of June 20, 2024: 6 items on PROTAGONIST THERAPEUTICS INC.’s Form 8-K, filed June 26, 2024: 3 approved · 3 without a stated outcome.

Material dissent

Elect Director: Sarah A. O’Dowd 54.9% of votes cast Outcome not stated Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore PROTAGONIST THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by PROTAGONIST THERAPEUTICS INC.

These tallies are PROTAGONIST THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 26, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

PROTAGONIST THERAPEUTICS INC. — official shareholder meeting results, meeting held June 20, 2024
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Sarah A. O’Dowd	23,937,874	--	--	19,687,632	6,186,924	54.9%	Not verified	—
Elect Director: William D. Waddill	40,485,630	--	--	3,139,876	6,186,924	93%	Not verified	—
Elect Director: Lewis T. “Rusty” Williams, M.D., Ph.D.	41,412,428	--	--	2,213,078	6,186,924	95%	Not verified	—
2. To approve, on an advisory basis, the compensation of the Company's named executive officers	33,929,884	9,335,699	359,923	--	6,186,924	78%	Approved	—
3. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2024	49,293,711	115,292	403,427	--	--	99.7%	Approved	—
4. To approve an amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of Common Stock from 90,000,000 to 180,000,000	47,200,237	278,523	2,333,670	--	--	99.4%	Approved	—

Source: PROTAGONIST THERAPEUTICS INC., Form 8-K, filed with the SEC on June 26, 2024 — read the filing on EDGAR.

How asset managers voted at the PROTAGONIST THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 209 asset managers that disclosed a PROTAGONIST THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Lewis T. “Rusty” Williams, M.D., Ph.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 41,412,428WITHHELD: 2,213,078

Details: description as filed, official tally, votes by 62 asset managers

Description as filed by funds: To elect the Class II director nominees named below to hold office until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Lewis T. "Rusty" Williams, M.D., Ph.D.

PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“Elect Director: Lewis T. “Rusty” Williams, M.D., Ph.D.”): 41,412,428 for, 2,213,078 withheld, per its Form 8-K filed June 26, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 12,673,842 for, 950,417 withheld, 13,734 abstained.

FOR

FOR: 12,673,842ABSTAIN: 13,734WITHHOLD: 950,417

Largest asset managers voting on “To elect the Class II director nominees named below to hold office until the 2027 Annual Meeting of Stockholde” at PROTAGONIST THERAPEUTICS INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	3,074,193	0	For
BlackRock	3,065,574	0	For
State Street	1,961,466	174	For
Fidelity	1,236,701	464,699	Mixed
T. Rowe Price	624,514	0	For
Charles Schwab	502,836	0	For
TIAA	473,993	0	For
Dimensional	0	425,437	Withhold
First Trust	154,672	0	For
Equitable	98,521	54,200	Mixed
Direxion Shares ETF Trust	130,315	0	For
JPMorgan	127,662	0	For
CARILLON SERIES TRUST	113,922	0	For
QUANTITATIVE MASTER SERIES LLC	106,465	0	For
Lincoln Financial	83,932	5,907	Mixed
American Century	87,424	0	For
SEI	70,414	0	For
Nushares ETF Trust	58,621	0	For
John Hancock	52,508	0	For
ProShares	49,787	0	For
Exchange Place Advisors Trust	49,238	0	For
Prudential/PGIM	48,353	0	For
DRIEHAUS MUTUAL FUNDS	45,028	0	For
ALPS ETF Trust	40,780	0	For
Pacific Life	40,067	0	For

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

2. Elect Director: Sarah A. O’Dowd

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

54.9% Majority: yes · of votes cast

FOR 54.9%WITHHELD

FOR: 23,937,874WITHHELD: 19,687,632

Details: description as filed, official tally, votes by 62 asset managers

PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“Elect Director: Sarah A. O’Dowd”): 23,937,874 for, 19,687,632 withheld, per its Form 8-K filed June 26, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 54.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 8,574,625 for, 4,857,063 withheld, 206,305 abstained.

FORWITHHOLD

FOR: 8,574,625ABSTAIN: 206,305WITHHOLD: 4,857,063

Largest asset managers voting on “To elect the Class II director nominees named below to hold office until the 2027 Annual Meeting of Stockholde” at PROTAGONIST THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Withheld	Vote
Vanguard	3,070,415	0	3,778	For
BlackRock	3,065,574	0	0	For
State Street	2,055	0	1,959,585	Withhold
Fidelity	1,233,801	0	467,599	Mixed
T. Rowe Price	624,514	0	0	For
Charles Schwab	0	0	502,836	Withhold
TIAA	0	0	473,993	Withhold
Dimensional	0	0	425,437	Withhold
First Trust	0	0	154,672	Withhold
Equitable	98,521	0	54,200	Mixed
Direxion Shares ETF Trust	0	0	130,315	Withhold
JPMorgan	127,662	0	0	For
CARILLON SERIES TRUST	0	113,922	0	Abstain
QUANTITATIVE MASTER SERIES LLC	106,465	0	0	For
Lincoln Financial	9,905	0	79,934	Mixed
American Century	0	0	87,424	Withhold
SEI	0	0	70,414	Withhold
Nushares ETF Trust	0	0	58,621	Withhold
John Hancock	31,501	21,007	0	Mixed
ProShares	0	0	49,787	Withhold
Exchange Place Advisors Trust	0	49,238	0	Abstain
Prudential/PGIM	48,353	0	0	For
DRIEHAUS MUTUAL FUNDS	0	0	45,028	Withhold
ALPS ETF Trust	0	0	40,780	Withhold
Pacific Life	40,067	0	0	For

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

3. Elect Director: William D. Waddill

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%

FOR: 40,485,630WITHHELD: 3,139,876

Details: description as filed, official tally, votes by 62 asset managers

PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“Elect Director: William D. Waddill”): 40,485,630 for, 3,139,876 withheld, per its Form 8-K filed June 26, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 12,673,842 for, 950,417 withheld, 13,734 abstained.

FOR

FOR: 12,673,842ABSTAIN: 13,734WITHHOLD: 950,417

Largest asset managers voting on “To elect the Class II director nominees named below to hold office until the 2027 Annual Meeting of Stockholde” at PROTAGONIST THERAPEUTICS INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	3,074,193	0	For
BlackRock	3,065,574	0	For
State Street	1,961,466	174	For
Fidelity	1,236,701	464,699	Mixed
T. Rowe Price	624,514	0	For
Charles Schwab	502,836	0	For
TIAA	473,993	0	For
Dimensional	0	425,437	Withhold
First Trust	154,672	0	For
Equitable	98,521	54,200	Mixed
Direxion Shares ETF Trust	130,315	0	For
JPMorgan	127,662	0	For
CARILLON SERIES TRUST	113,922	0	For
QUANTITATIVE MASTER SERIES LLC	106,465	0	For
Lincoln Financial	83,932	5,907	Mixed
American Century	87,424	0	For
SEI	70,414	0	For
Nushares ETF Trust	58,621	0	For
John Hancock	52,508	0	For
ProShares	49,787	0	For
Exchange Place Advisors Trust	49,238	0	For
Prudential/PGIM	48,353	0	For
DRIEHAUS MUTUAL FUNDS	45,028	0	For
ALPS ETF Trust	40,780	0	For
Pacific Life	40,067	0	For

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

4. 4. To approve an amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of…

Official result Fund totals may overlapCAPITAL STRUCTUREReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.4% Approved · of votes cast

FOR 99.4%

FOR: 47,200,237AGAINST: 278,523

Details: description as filed, official tally, votes by 66 asset managers

Description as filed by funds: To approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our common stock from 90,000,000 to 180,000,000.

PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“4. To approve an amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of Common Stock from 90,000,000 to 180,000,000”): 47,200,237 for, 278,523 against — passed, per its Form 8-K filed June 26, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote, with the votes thereon as follows:”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 63 asset managers voting on “To approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our” at PROTAGONIST THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	3,074,193	0	For
BlackRock	3,065,574	0	For
State Street	1,961,562	78	For
Fidelity	1,701,400	0	For
T. Rowe Price	624,514	0	For
Charles Schwab	502,836	0	For
TIAA	473,993	0	For
Dimensional	425,437	0	For
First Trust	154,672	0	For
Equitable	152,721	0	For
Direxion Shares ETF Trust	130,315	0	For
JPMorgan	127,662	0	For
CARILLON SERIES TRUST	113,922	0	For
QUANTITATIVE MASTER SERIES LLC	106,465	0	For
Lincoln Financial	89,839	0	For
American Century	87,424	0	For
SEI	70,414	0	For
Nushares ETF Trust	58,621	0	For
John Hancock	52,508	0	For
ProShares	49,787	0	For
Exchange Place Advisors Trust	49,238	0	For
Prudential/PGIM	48,353	0	For
DRIEHAUS MUTUAL FUNDS	45,028	0	For
ALPS ETF Trust	40,780	0	For
Pacific Life	40,067	0	For

Fund voting reports, all 63 managers: 13,650,005 for, 78 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 3 asset managers voting on “To approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our” at PROTAGONIST THERAPEUTICS INC., 2023-2024
Asset manager	For	Withheld	Vote
Kynam Capital Management, LP	0	1,013,018	Withhold
Resolute Capital Asset Partners LLC	39,500	0	For
Jackson Creek Investment Advisors LLC	1,609	0	For

Institutional-manager reports, all 3 managers: 41,109 for, 1,013,018 withheld.

5. 2. To approve, on an advisory basis, the compensation of the Company's named executive officers

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

78% Approved · of votes cast

FOR 78%AGAINST

FOR: 33,929,884AGAINST: 9,335,699

Details: description as filed, official tally, votes by 209 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers.

PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“2. To approve, on an advisory basis, the compensation of the Company's named executive officers”): 33,929,884 for, 9,335,699 against — passed, per its Form 8-K filed June 26, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote, with the votes thereon as follows:”
Support: 78% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports: 63 asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers.” at PROTAGONIST THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	3,074,193	0	For
BlackRock	3,065,574	0	For
State Street	1,961,194	446	For
Fidelity	1,236,701	464,699	Mixed
T. Rowe Price	624,514	0	For
Charles Schwab	502,836	0	For
TIAA	473,993	0	For
Dimensional	0	425,437	Against
First Trust	154,672	0	For
Equitable	152,721	0	For
Direxion Shares ETF Trust	130,315	0	For
JPMorgan	127,662	0	For
CARILLON SERIES TRUST	113,922	0	For
QUANTITATIVE MASTER SERIES LLC	106,465	0	For
Lincoln Financial	83,932	5,907	Mixed
American Century	0	87,424	Against
SEI	0	70,414	Against
Nushares ETF Trust	58,621	0	For
John Hancock	52,508	0	For
ProShares	49,787	0	For
Exchange Place Advisors Trust	0	49,238	Against
Prudential/PGIM	0	48,353	Against
DRIEHAUS MUTUAL FUNDS	45,028	0	For
ALPS ETF Trust	40,780	0	For
Pacific Life	40,067	0	For

Fund voting reports, all 63 managers: 12,402,137 for, 1,247,946 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 166 asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers.” at PROTAGONIST THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
FARALLON CAPITAL MANAGEMENT LLC	0	5,605,285	0	0	Against
BVF INC/IL	3,566,270	0	0	0	For
State Street	3,083,203	613	0	0	For
RTW INVESTMENTS, LP	2,817,667	0	0	0	For
Johnson & Johnson Innovation - JJDC, Inc.	2,449,183	0	0	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	2,238,868	0	0	0	For
BlackRock	1,864,072	13,787	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,299,437	0	0	0	For
Kynam Capital Management, LP	0	0	0	1,013,018	Withhold
Fairmount Funds Management LLC	931,890	0	0	0	For
T. Rowe Price	836,192	0	0	0	For
Point72	719,781	0	0	0	For
683 Capital Management, LLC	700,000	0	0	0	For
MARSHALL WACE, LLP	0	665,424	0	0	Against
Woodline Partners LP	541,387	0	0	0	For
Nuveen	536,209	0	0	0	For
Charles Schwab	502,836	0	0	0	For
Fidelity	0	467,852	0	0	Against
Northern Trust	460,666	39	0	0	For
PERCEPTIVE ADVISORS LLC	440,226	0	0	0	For
DRIEHAUS CAPITAL MANAGEMENT LLC	438,690	0	0	0	For
UBS	42,587	321,529	0	0	Mixed
EAGLE ASSET MANAGEMENT INC	361,090	0	0	0	For
Candriam S.C.A.	0	360,000	0	0	Against
MANGROVE PARTNERS IM, LLC	0	0	337,137	0	Abstain

Institutional-manager reports, all 166 managers: 26,848,691 for, 8,467,798 against, 1,013,018 withheld, 337,137 abstained, 1,328 not voted. Showing the 25 largest; see all in the interactive database.

6. 3. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.7% Approved · of votes cast

FOR 99.7%

FOR: 49,293,711AGAINST: 115,292

Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“3. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2024”): 49,293,711 for, 115,292 against — passed, per its Form 8-K filed June 26, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote, with the votes thereon as follows:”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 13,651,692 for.

FOR

FOR: 13,651,692

Largest asset managers voting on “To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fisc” at PROTAGONIST THERAPEUTICS INC., 2023-2024
Asset manager	For	Vote
Vanguard	3,074,193	For
BlackRock	3,065,574	For
State Street	1,961,640	For
Fidelity	1,701,400	For
T. Rowe Price	624,514	For
Charles Schwab	502,836	For
TIAA	473,993	For
Dimensional	425,437	For
First Trust	154,672	For
Equitable	152,721	For
Direxion Shares ETF Trust	130,315	For
JPMorgan	127,662	For
CARILLON SERIES TRUST	113,922	For
QUANTITATIVE MASTER SERIES LLC	106,465	For
Lincoln Financial	89,839	For
American Century	87,424	For
SEI	70,414	For
Nushares ETF Trust	58,621	For
John Hancock	52,508	For
ProShares	49,787	For
Exchange Place Advisors Trust	49,238	For
Prudential/PGIM	48,353	For
DRIEHAUS MUTUAL FUNDS	45,028	For
ALPS ETF Trust	40,780	For
Pacific Life	40,067	For

Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.

Largest PROTAGONIST THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 58,600,787 shares outstanding at the time of that meeting.

Fund voting reports: top PROTAGONIST THERAPEUTICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our named executive officers.”, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	5.25%
2	BlackRock	5.23%
3	State Street	3.35%
4	Fidelity	2.90%
5	T. Rowe Price	1.07%
6	Charles Schwab	0.86%
7	TIAA	0.81%
8	Dimensional	0.73%
9	First Trust	0.26%
10	Equitable	0.26%

Institutional-manager reports: top PROTAGONIST THERAPEUTICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our named executive officers.”, 2023-2024
#	Asset manager	% of shares outstanding
1	FARALLON CAPITAL MANAGEMENT LLC	9.57%
2	BVF INC/IL	6.09%
3	State Street	5.26%
4	RTW INVESTMENTS, LP	4.81%
5	Johnson & Johnson Innovation - JJDC, Inc.	4.18%
6	ADAGE CAPITAL PARTNERS GP, L.L.C.	3.82%
7	BlackRock	3.20%
8	GEODE CAPITAL MANAGEMENT, LLC	2.22%
9	Kynam Capital Management, LP	1.73%
10	Fairmount Funds Management LLC	1.59%

Reported PROTAGONIST THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

PROTAGONIST THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
BlackRock	16.05%	13F
Vanguard Group	7.26%	13F
State Street	5.58%	13F
Geode Capital	2.21%	13F
Point72	2.05%	13F
T. Rowe Price	1.40%	13F
Dimensional Fund Advisors	1.35%	13F
Goldman Sachs	1.33%	13F
Morgan Stanley	1.31%	13F
Nuveen	1.16%	13F

Percentages above are of 58,600,787 shares outstanding, as reported by PROTAGONIST THERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PROTAGONIST THERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At PROTAGONIST THERAPEUTICS INC.'s shareholder meeting held June 20, 2024, in the 2023-2024 proxy season, 209 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,450 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers. — PROTAGONIST THERAPEUTICS INC.'s filing reports the proposal as approved, with 78% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: PROTAGONIST THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 26, 2024.

PROTAGONIST THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.